An FDA Advisory panel just gave a positive recommendation on Novartis' CAR T treatment for cancer. Novartis reports that 75% of terminally ill cancer patients that received treatment are cancer free. This is the most exciting advancement in medicine of our lifetimes. The big challenge will be price point. CAR T treatment is personalized medicine and so it's very expensive. Novartis chart does not look like a good setup right now IMO. I'd like to see more consolidation and evidence large players are buying before taking an entry.